All In Biotech

Drug Trial Radar · NCT01058174

Liver Transplant European Study Into the Prevention of Fungal Infection

Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Dec 15, 2009

Primary completion

May 3, 2012

Study completion May 3, 2012

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jan 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prevention of invasive fungal infection in high risk patients following liver transplant.

Conditions

  • Liver Transplantation
  • Mycoses

Interventions

  • micafunginDrug

    intravenous infusion

  • fluconazoleDrug

    intravenous infusion

  • liposomal amphotericin BDrug

    intravenous infusion

  • caspofunginDrug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 'Clinical success' at the End of Prophylaxis as assessed by the Independent Data Review Board (IDRB).Time frame: up to 21 days

Locations

36 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Innsbruck, Austria

  • Site not named

    Antwerp, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Clichy, France

  • Site not named

    Paris, France

  • Site not named

    Toulouse, France

  • Site not named

    Paris, Villejuif Cedex, France

  • Site not named

    Berlin, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Heidelberg, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Dublin, Ireland

  • Site not named

    Milan, Italy

  • Site not named

    Padova, Italy

  • Site not named

    Torino, Italy

  • Site not named

    Udine, Italy

  • Site not named

    Coimbra, Portugal

  • Site not named

    Porto, Portugal

  • Site not named

    Bucharest, Romania

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Riyadh, Saudi Arabia

  • Site not named

    Barcelona, Spain

  • Site not named

    Córdoba, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Valencia, Spain

  • Site not named

    Santiago de Compostela, A Coruna, Spain

  • Site not named

    Barakald, Vicaya, Spain

  • Site not named

    Stockholm, Sweden

  • Site not named

    Birmingham, United Kingdom

  • Site not named

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.